Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia.
about
Bone Marrow Immunity and MyelodysplasiaInfections in myelodysplastic syndromesDeregulation of innate immune and inflammatory signaling in myelodysplastic syndromesThe relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases.Immunosuppressive treatments for myelodysplastic syndromes.CXCR4 expression on pathogenic T cells facilitates their bone marrow infiltration in a mouse model of aplastic anemiaImmune dysregulation in myelodysplastic syndrome.Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndromeA new aspect of the molecular pathogenesis of paroxysmal nocturnal hemoglobinuria.Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndromeMyelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts.Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemiaPhenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia.Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndromeImmune alterations in untreated and treated myelodysplastic syndrome.Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.Mesenchymal stem cells in immune-mediated bone marrow failure syndromes.Blessing or curse? Proteomics in granzyme research.Novel deletion mutation of HLA-B*40:02 gene in acquired aplastic anemia.CD8+ T cells drive autoimmune hematopoietic stem cell dysfunction and bone marrow failure.Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes.Expression of CXCR4 on T-cell subsets and Plasma IL-17 Concentrations in Patients with Aplastic Anaemia.Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome.Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia.PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model.Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies.Large granular lymphocyte (LGL)-like clonal expansions in paroxysmal nocturnal hemoglobinuria (PNH) patients.Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cellsActivated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia
P2860
Q26739239-909BCAD4-4286-4A21-8BE8-B3FA09717737Q26859275-0349216B-671C-422B-B5B3-4FDA13EFB56BQ27015288-BB8846A8-FAD9-4C05-87E2-7C6367ACBAA9Q33442467-49504E2B-DB90-461C-ACD3-CFF69F322845Q33679140-450ED0E2-CE37-469F-B662-C3DDF4D0234AQ33702157-3653A934-6BCC-412F-BB2E-F1547ABE0082Q35004399-94ACB39F-C716-4AA2-926C-2678BAC71327Q35126995-7A16B59D-6F0A-407B-9F9A-2AE570BF9E55Q35137166-AFBB958F-97E9-4B90-9012-9CE1CB7BFABDQ35220648-84C725A5-302F-4D91-BE54-6FACEFCB2A91Q35567932-CB37541E-BCB4-499D-BE96-E52A9D60C53CQ35657367-F6ACE9F7-B004-48B2-80CE-C2E0116D57A8Q35670980-F1B8F94E-6955-427A-BCC1-6D6F1E1F8218Q35849198-680462F5-B4B4-4A7E-8BF4-7AE234D9D194Q35912886-494B452E-9EC6-440D-80FF-01AB32E7BEF6Q36973664-20AD98CF-90F2-455A-B852-75F89E4F7BDEQ37069554-9A77EF32-4CD7-45CD-B22D-840E3540EC98Q37146038-C2ED5692-2587-4EE5-AF00-F5C04C2E4482Q37584833-0C03668E-1A89-4E84-9133-DFEA8168D9B4Q37854701-B19F59D6-0065-4F09-8E03-722417D3F526Q37864686-A00C3DBF-8FC5-47C8-8CB4-3A0E98061619Q37895329-A91D85A0-252A-450D-9B2C-8F89AE994CC1Q37937816-0F4A5852-81EC-42C4-B33C-CAAC1F13C6F1Q38175397-65FAFDA4-0C30-4D51-84A9-3D0AD18C9CA4Q38200060-2BEB481F-C9E2-4364-A754-F3B8FA3898B0Q39062911-C56A1752-176D-4374-A0FB-579F6FB2553EQ39565006-E44F5F71-3B88-46AF-A0A3-4C29BDF7284CQ40592382-D16B7228-63AA-4454-90D2-088C15663E42Q41489911-B94428C9-5AFA-46F0-89B3-4B3072456ADDQ42036124-9CD73824-1D2C-4D55-862F-BA99FC66E3B2Q42144212-08A55458-AAC4-4EF3-B3C0-ACC8C5AE37BBQ42527369-60D97F6F-5D02-4D31-B5DD-7B4E7D2B68AEQ42541218-DA6C8A3A-BB2D-44F2-8337-2D579A6A0FC2Q50118878-F22FEF2D-7BCB-4A9A-8C1F-60362B964771Q50531427-43EC9C3E-199C-43E8-8E2C-C015E7FB3C76Q53509758-634C3F31-DA2D-4A0E-ADED-121092D88A4AQ54683819-ECAFFC54-D194-4B32-876C-1F9DB3CD7205Q56777872-2A188835-B464-4A94-B7F4-F26650FCCCECQ58041641-89C7DDDA-0760-499A-86E0-5225EAA22F25
P2860
Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Increased cytotoxic T cells wi ...... tic anemia and myelodysplasia.
@en
Increased cytotoxic T cells wi ...... tic anemia and myelodysplasia.
@nl
type
label
Increased cytotoxic T cells wi ...... tic anemia and myelodysplasia.
@en
Increased cytotoxic T cells wi ...... tic anemia and myelodysplasia.
@nl
prefLabel
Increased cytotoxic T cells wi ...... tic anemia and myelodysplasia.
@en
Increased cytotoxic T cells wi ...... tic anemia and myelodysplasia.
@nl
P2093
P1476
Increased cytotoxic T cells wi ...... tic anemia and myelodysplasia.
@en
P2093
P304
P356
10.1016/S0301-472X(01)00736-6
P577
2001-11-01T00:00:00Z